Beijing Tri Prime Gene Pharmaceutical (BJ:837344) Xin Jing Bao·2025-09-07 14:32Core Viewpoint - Beijing Sanyuan Gene Pharmaceutical Co., Ltd. has completed the research and development of recombinant human collagen and is preparing for registration application, marking a strategic expansion into the consumer healthcare market [1][2]. Group 1: Company Developments - The company has achieved breakthroughs in protein molecular weight, amino acid sequence, triple helix structure, and expression system with recombinant human collagen, positioning it as an ideal material for beauty fillers and tissue repair scaffolds [1]. - The collagen market is projected to grow from 18.5 billion yuan in 2022 to 108.3 billion yuan by 2027, indicating a shift in focus towards "beauty and health" in the wellness sector [1]. - Sanyuan Gene plans to increase R&D investment and advance the registration of collagen-related cosmetics and medical devices, aiming for a phased market launch of collagen series products [1]. Group 2: Financial Performance - As of June 30, 2025, the company reported revenue of approximately 118 million yuan, a year-on-year increase of 1.02%, while the net profit attributable to shareholders was approximately -6.47 million yuan, a decline of 166.89% [2]. - In the second quarter of 2025, the company achieved a net profit of 5.79 million yuan, with a 62.89% quarter-on-quarter increase in revenue, attributed to enhanced sales management and market expansion efforts [2].